Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

CMS Officials Pressed on Catheter Fraud Issue at Accountable Care Meeting

The Centers for Medicare & Medicaid Services (CMS) officials speaking on a panel at an annual gathering of accountable care organizations (ACOs) in Baltimore were

April 13, 2024

Empathetic correction of misinformation can improve attitudes towards vaccination, study shows

An international study has shown for the first time how empathetic correction of misinformation among vaccine-hesitant patients can significantly improve attitudes towards vaccination – and

March 4, 2024

AI Assistant Reduces Clinician Burnout at Children’s Hospital of Los Angeles

What You Should Know: Nabla, the company developing Nabla Copilot, the leading ambient AI assistant for clinicians, today announced it has partnered with Children’s Hospital Los Angeles (CHLA) to roll

March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.